These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 29617965)

  • 1. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
    Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
    J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
    Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
    Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
    BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries.
    Kowada A
    Travel Med Infect Dis; 2016; 14(5):489-498. PubMed ID: 27238907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    Am J Respir Crit Care Med; 2009 Jun; 179(11):1055-60. PubMed ID: 19299495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
    Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
    Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Nov; 30(11):1410-1417. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
    Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
    AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India.
    Kapoor S; Gupta A; Shah M
    Int J Tuberc Lung Dis; 2016 Jan; 20(1):85-92. PubMed ID: 26688533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
    Cao X; Guo T; Xin H; Du J; Yang C; Feng B; He Y; Shen L; Di Y; Li Z; Chen Y; Liang J; Jin Q; Wang L; Gao L
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):809-820. PubMed ID: 38383889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.